
Sacubitril/Valsartan and Heart Failure, Prior SARS-CoV-2 Infection and Breakthrough Infection Following mRNA Vaccination, COVID-19 and In-Hospital Mortality With Myocardial Infarction, and more
JAMA Editors' Summary
00:00
Introduction
This is the jama editor's summary, a review of important research and review articles appearing in the latest jama issue. The parallax randomized clinical trial found that secubitre val sartan significantly reduced nt probian p levels compared with standard therapes. This therap did not significantly increase six minute walking distance or the kansas city cardimaopathy questionair summary score which is a measure of quality of life.
Transcript
Play full episode